{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04586270",
            "orgStudyIdInfo": {
                "id": "TAS0612-101"
            },
            "secondaryIdInfos": [
                {
                    "id": "2020-002304-39",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Taiho Oncology, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer",
            "officialTitle": "A Phase 1 Study of TAS0612 in Patients With Locally Advanced or Metastatic Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-in-participants-with-advanced-or-metastatic-solid-tumor-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-10-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-09-23",
            "studyFirstSubmitQcDate": "2020-10-13",
            "studyFirstPostDateStruct": {
                "date": "2020-10-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-27",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Taiho Oncology, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to see if TAS0612 is safe in participants with advanced or metastatic solid tumor cancer."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced or Metastatic Solid Tumors"
            ],
            "keywords": [
                "Solid Tumors",
                "AKT inhibitor",
                "RSK inhibitor",
                "S6K inhibitor",
                "kinase inhibitor",
                "phase I",
                "Prostate cancer",
                "PTEN loss",
                "PTEN mutation"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "TAS0612 Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "TAS0612 administered orally",
                    "interventionNames": [
                        "Drug: TAS0612"
                    ]
                },
                {
                    "label": "TAS0612 Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "TAS0612 administered orally",
                    "interventionNames": [
                        "Drug: TAS0612"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "TAS0612",
                    "description": "oral tablets",
                    "armGroupLabels": [
                        "TAS0612 Escalation",
                        "TAS0612 Expansion"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Dose Limiting Toxicities (DLTs)",
                    "description": "Number of participants with DLTs during cycle 1",
                    "timeFrame": "Baseline through Cycle 1 (28-day cycle)"
                },
                {
                    "measure": "rPFS rate",
                    "description": "Percentage of participants with partial response (PR) or complete response (CR) at 6 months Prostate Cancer Working Group 3 (PCWG3)/ modified defined by the Response Evaluation Criteria in Solid Tumors (mRECIST) v1.1.",
                    "timeFrame": "Baseline through measured progressive disease (estimated up to 12 months)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Disease Control Rate (DCR) per PCWG3/mRECIST1.1",
                    "description": "DCR: Percentage of participants who exhibit stable disease (SD), PR or CR.",
                    "timeFrame": "Baseline through progressive disease or date of death for any causes, whichever comes first, assessed up to 12 months."
                },
                {
                    "measure": "Duration of Response (DOR) per PCWG3/mRECIST1.1",
                    "description": "DOR: Date of PR or CR to date of objective progression or death due to any cause.",
                    "timeFrame": "Baseline through progressive disease or date of death for any causes, whichever comes first, assessed up to 12 months."
                },
                {
                    "measure": "Radiographic Progression Free Survival (rPFS) per PCWG3/mRECIST1.1",
                    "description": "Proportion of patients experiencing a radiographic progression by PCWG3/mRECIST1.1 criteria",
                    "timeFrame": "Baseline through progressive disease or date of death for any causes, whichever comes first, assessed up to 6 months."
                },
                {
                    "measure": "Overall Response Rate (ORR) per PCWG3/mRECIST1.1",
                    "description": "Proportion of patients experiencing a best overall response of Complete Response (CR) or Partial response (PR)",
                    "timeFrame": "Baseline through progressive disease or date of death for any causes, whichever comes first, assessed up to 12 months."
                },
                {
                    "measure": "Prostatic Specific Antigen (PSA) Response",
                    "description": "Proportion of patients with \u226550% reduction in PSA from baseline to lowest post-baseline result.",
                    "timeFrame": "Baseline to PSA progression, up to 12 months"
                },
                {
                    "measure": "Pharmacokinetics (PK) parameters including but not limited to: Cmax",
                    "description": "time of TAS0612 it takes to reach Cmax.",
                    "timeFrame": "Cycle 1 Day 1 through Cycle 1 Day 15 (28-day cycle) Cycle 2 Day 1 and Cycle 3 Day 1"
                },
                {
                    "measure": "Pharmacokinetics (PK) parameters including but not limited to: Tmax",
                    "description": "time of TAS0612 it takes to reach Cmax,",
                    "timeFrame": "Cycle 1 Day 1 through Cycle 1 Day 15 (28-day cycle) Cycle 2 Day 1 and Cycle 3 Day 1"
                },
                {
                    "measure": "Pharmacokinetics (PK) parameters including but not limited to: AUC.",
                    "description": "Area under the plasma concentration curve of TAS0612.",
                    "timeFrame": "Cycle 1 Day 1 through Cycle 1 Day 15 (28-day cycle) Cycle 2 Day 1 and Cycle 3 Day 1"
                },
                {
                    "measure": "Pharmacokinetics (PK) parameters including but not limited to: T1/2.",
                    "description": "time it takes for plasma concentration to fall by half its original value (t1/2) of TAS0612",
                    "timeFrame": "Cycle 1 Day 1 through Cycle 1 Day 15 (28-day cycle) Cycle 2 Day 1 and Cycle 3 Day 1"
                },
                {
                    "measure": "Safety and Tolerability",
                    "description": "All adverse events (AEs) per CTCAE v5.0.",
                    "timeFrame": "From screening to 30 days after last dose"
                },
                {
                    "measure": "Pharmacodynamic: biochemical effects of TAS0612: Total proteins",
                    "description": "Total proteins will be measured in blood samples collected at different time points.",
                    "timeFrame": "Cycle 1 Day 1 through Cycle 1 Day 15 (28-day cycle)"
                },
                {
                    "measure": "Pharmacodynamic: biochemical effects of TAS0612: phospho-proteins",
                    "description": "Phospho-proteins will be measured in blood samples collected at different time points. The levels/changes (dose- and concentration-dependent) of phospho-proteins will be assessed and reported for biochemical effects of TAS0612.",
                    "timeFrame": "Cycle 1 Day 1 through Cycle 1 Day 15 (28-day cycle)"
                },
                {
                    "measure": "Pharmacodynamic: molecular effects in tumor tissue of TAS0612",
                    "description": "Selected phospho-proteins will be analyzed in tumor tissue at baseline and on-treatment in dose escalation. The levels/changes of the phospho-proteins will be assessed and reported for target modulation.",
                    "timeFrame": "Baseline through Day 1 Cycle 2 (28-day cycle) through study completion, an average of 1 year"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Pharmacokinetics (PK): Metabolites in plasma",
                    "description": "Structure elucidation of TAS0612 metabolites in human plasma.",
                    "timeFrame": "Cycle 1 Day 1 (each cycle is 28 days)."
                },
                {
                    "measure": "Time-matched plasma exposures of TAS0612 and changes from baseline in QTcF using central ECG measurements",
                    "description": "To explore the correlation between the incidence of exposures of TAS0612 in plasma and QT prolongation",
                    "timeFrame": "Baseline through progressive disease or date of death for any causes, whichever comes first, assessed up to 12 months"
                },
                {
                    "measure": "Exploratory correlation of tissue and/or blood markers with tumor efficacy endpoints and/or tumor resistance to TAS0612",
                    "description": "To investigate potential predictive biomarkers for TAS0612.",
                    "timeFrame": "Baseline through progressive disease or date of death for any causes, whichever comes first, assessed up to 12 months."
                },
                {
                    "measure": "Exposure of TAS0612 and selected efficacy and safety measures.",
                    "description": "To explore the correlation between PK and antitumor activity or toxicity",
                    "timeFrame": "Baseline through progressive disease or date of death for any causes, whichever comes first, assessed up to 12 months."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nDose Escalation:\n\nHave histologically confirmed, locally advanced, and unresectable cancer, or metastatic cancer and have progressed on or were intolerant to standard treatments or refused standard of care (SOC).\n\nDose Expansion:\n\nHave documented histologically or cytologically confirmed adenocarcinoma of the prostate with documented PTEN loss or loss of function mutation, who have metastatic castration-resistant disease and have:\n\n* Disease progression per the Prostate Cancer Clinical Trials Working Group 3 (PCWG3)/modified RECIST 1.1 after the most recent regimen.\n* Received androgen receptor directed therapy previously with or without chemotherapy consisting of no more than 2 prior taxane-based regimens.\n* Been receiving androgen deprivation therapy with serum testosterone \\<50 ng/dL (\\<2.0 nM). Note: previously documented PTEN loss or loss of function mutation from archived tissue sample testing or cfDNA sample testing is acceptable if done in a CLIA certified lab or a locally certified lab.\n\nHave an ECOG score of 0 or 1 Dose Escalation (Part 1): Have no measurable or measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n\nDose Expansion (Part 2): Have measurable or no measurable disease per PCWG3/modified RECIST 1.1\n\n\u2022 No more than 30 patients with no measurable disease will be enrolled in Dose Expansion (Part 2).\n\nExclusion Criteria:\n\n* Participating in medical research not compatible with this study\n* Have not discontinued or recovered from previous treatments for cancer\n* Have a significant cardiac condition\n* Have untreated brain metastases\n* Have a primary brain tumor\n* Have a serious concomitant disorder\n* Unable to swallow or digest pills\n* Poorly controlled diabetes\n* Concomitant medications or substances that are strong inhibitors/inducers of CYP3A.Study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Taiho Oncology, INC",
                    "role": "CONTACT",
                    "phone": "844-878-2446",
                    "email": "medicalinformation@taihooncology.com"
                }
            ],
            "locations": [
                {
                    "facility": "Tennessee Oncology",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "erika.hamilton@scri.com"
                        },
                        {
                            "name": "Erika Hamilton",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "University of Texas MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "fmeric@mdanderson.org"
                        },
                        {
                            "name": "Funda Meric-Bernstam",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Institut Paoli Calmette",
                    "status": "RECRUITING",
                    "city": "Marseille",
                    "state": "Bouches Du Rhone",
                    "zip": "13009",
                    "country": "France",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "VICIERC@ipc.unicancer.fr"
                        },
                        {
                            "name": "Cecile Vicier",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.29551,
                        "lon": 5.38958
                    }
                },
                {
                    "facility": "Centre de Lutte Contre le Cancer Gustave Roussy",
                    "status": "RECRUITING",
                    "city": "Villejuif",
                    "state": "Val De Marne",
                    "zip": "94805",
                    "country": "France",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "(+33) 01 42 11 42 11"
                        },
                        {
                            "name": "Capucine Baldini",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.7939,
                        "lon": 2.35992
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}